Merck, Glenmark forge Zetia patent settlement; Ranbaxy beats quarterly estimates;

 @FiercePharma: Novartis CEO goes on a 'decluttering' drive. Report | Follow @FiercePharma

> Merck has agreed to let Glenmark Pharmaceuticals sell a generic version of the cholesterol medicine Zetia in the U.S. by December 2016 as part of a settlement of a patent-infringement lawsuit. Release | Report

> India's Ranbaxy Laboratories raced past estimates with its fourth straight quarterly profit and kept ambitious earnings forecasts unchanged for the year. Report

> Drug shortages in the U.K. could remain into next year as parallel traders continue to cash in on the weak pound, according to British Association of European Pharmaceutical Distributors. Report

> Salix Pharmaceuticals' first-quarter loss widened less than it had expected, and the drugmaker also projected a second-quarter profit, which would be its first time in the black in more than two years. Report

> Indian outsourcing provider HCL Technologies has announced a $500 million, five-year deal with Merck, through which HCL will providing BPO, KPO and engineering services. Report

> Purdue Pharma has filed a patent infringement suit against India's Ranbaxy, after the latter applied for marketing approval of a low-cost version of Purdue's pain medicine Oxycodone. Report

Biotech News

 @FierceBiotech: Frenchay Hospital trials offer MS stem cell hopes. Article | Follow @FierceBiotech

 @JohnCFierce:  Tiny Avexa has buried its HIV therapy, demolishing its share price and leaving it scrambling for a survival strategy. Article | Follow @JohnCFierce

> NicOx shares dive after regulators question naproxcinod's benefits. Report

> 'New Merck' spotlights late-stage strategy but shelves biosimilar. Item

> Roche adds $201M in milestones to Galapagos R&D pact. Story

> Test maker's shares soar on GSK cancer pact. Article

> Mayo team discovers new diabetes drug class. News

Manufacturing News

> "Concerned" J&J hopes to stop monthly Tylenol recalls. Story

> Drugmakers: Trypsin likely culprit in Rotavirus vax contamination. News

> Teva, Baxter fined $500M for propofol-vial reuse infections. Report

> Chinese heparin maker's stock falls after strong debut. News

> Findings could aid vax distribution in developing nations. Item

Biotech Research News

> Mayo investigators discover a new class of diabetes drugs. Report

> Aging expert heralds new class of therapeutics. Article

> Senate panel mulls NIH drug development plan. News

> Researchers measure pain in the expressions of lab mice. Story

And Finally... In the race to find answers about ovarian cancer, researchers now have something to cluck about. Report 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.